Encouraged by the apparent potential that when CD70 expression intensity exceeds 1.6, patients may benefit from nb70CAR-T therapy, we detected the expression level of CD70 on AML blast in more clinical samples to evaluate the clinical prospect of nb70CAR-T in the treatment of AML. Here, CD70 is linked to acute myeloid leukemia.